Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 4/2006

01-07-2006 | Case Report

Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman–Sacks endocarditis: a case for antibiotic prophylaxis?

Authors: David Armstrong, Stephen Wright, Claire McVeigh, Michael Finch

Published in: Clinical Rheumatology | Issue 4/2006

Login to get access

Abstract

We report a 54 year old female whose successful treatment of cerebral lupus with rituximab was complicated by the development of streptococcus intermedius, on valves damaged by Libman-Sacks endocarditis more than 20 years previously.
Literature
1.
Li JS, Sexton DJ, Mick N et al (2000) Proposed modifications to the duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30:633CrossRefPubMed
2.
Bijl M, Brouwer J, Kallenberg GG (2000) Cardiac abnormalities in SLE: pancarditis. Lupus 9(4):236–240CrossRefPubMed
3.
Straaton KV, Chatham WW, Reveille JD, Koopman WJ, Smith SH (1988 ) Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med 85(5):645–650PubMedCrossRef
4.
Miller CS, Egan RM, Falace DA, Rayens MK, Moore CR (1999) Prevalence of infective endocarditis in patients with systemic lupus erythematosus. J Am Dent Assoc 130(3):387–392PubMed
5.
Foran JM, Ratiner AZS, Cunningham D et al (2000) European Phase II study of rituximab (chimeric anti–CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317–324PubMed
6.
Ghielmini M, Schmitz SF, Burki K et al (2000) The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1:123–126CrossRef
7.
Faderl S, Thomas DA, O'Brien S et al (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413–3415CrossRefPubMed
8.
Frangogiannis NG, Cate TR (1998) Endocarditis and ureaplasma urealyticum osteomyelipits in a hypogammaglobulinaemia patient. A case report and review of the literature. J Infect 37:181–184CrossRefPubMed
9.
Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673–2677CrossRefPubMed
10.
Weide R, Heymans J, Pandorf A, Koppler H (2003) Successful long-term treatment of SLE with Rituximab maintainance therapy. Lupus 12:779–782CrossRefPubMed
11.
Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with Rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581CrossRefPubMed
Metadata
Title
Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman–Sacks endocarditis: a case for antibiotic prophylaxis?
Authors
David Armstrong
Stephen Wright
Claire McVeigh
Michael Finch
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0031-2

Other articles of this Issue 4/2006

Clinical Rheumatology 4/2006 Go to the issue

Case Report

Double-filtration plasmapheresis for resolution of corticosteroid resistant adult onset still's disease

Brief Report

Cytomegalovirus-induced small-bowel hemorrhage in a patient with nonsystemic vasculitic neuropathy

Original Article

Adrenal axis functions in patients with familial Mediterranean fever

Brief Report

Remitting seronegative symmetrical synovitis pitting oedema after BCG instillation

Review Article

Management of musculoskeletal complications in endstage renal disease: an update

Case Report

Treatment of therapy-resistant sarcoidosis with adalimumab
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits